People · Operator

Timothy C. Sarhatt

Named in public records as an officer, director or promoter · active 2014–2014 · Biotechnology

1
Companies
1
Filings
$20.9M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Tissue Genesis IncBiotechnologySeries A$20.9M$18.1M2014
Operator network

Timothy C. Sarhatt at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Anton C. Krucky · 1 companies · 1 sharedAnton C. KruckyBradley C. Perkins · 1 companies · 1 sharedBradley C. PerkinsHiam Robert · 1 companies · 1 sharedHiam RobertJeff C. Watanabe · 1 companies · 1 sharedJeff C. WatanabeJeffery C. Watanabe · 1 companies · 1 sharedJeffery C. Watana…Jeffrey C Watanabe · 1 companies · 1 sharedJeffrey C WatanabeLawrence C. Rodriguez · 1 companies · 1 sharedLawrence C. Rodri…Michael C. Ruley · 1 companies · 1 sharedMichael C. RuleyPaul C. Kosnik · 1 companies · 1 sharedPaul C. KosnikRobert C. Hiam · 1 companies · 1 sharedRobert C. HiamRobert Hiam · 1 companies · 1 sharedRobert HiamThomas C. Cannon · 1 companies · 1 sharedThomas C. CannonWilliam C. Wiesmann · 1 companies · 1 sharedWilliam C. Wiesma…Tissue Genesis Inc · $20.9M raisedTissue Genesis IncTimothy C. SarhattTS
Timothy C. Sarhatt Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Timothy C. Sarhatt on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Bradley C. Perkins11
Michael C. Ruley11
Paul C. Kosnik11
Anton C. Krucky11
Robert C. Hiam11
Jeffery C. Watanabe11
Thomas C. Cannon11
William C. Wiesmann11
Jeff C. Watanabe11
Jeffrey C Watanabe11
Robert Hiam11
Hiam Robert11
Lawrence C. Rodriguez11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.